risk of pancreatitis with semaglutide Frontiers What is the comparative risk

Ozempic (semaglutide) is a prescription medicine used to improve blood sugar control in adults with type 2 diabetes mellitus

At the time of the first visit, no patient had other known comorbidities

The results were consistent and sobering: Within one year of stopping, participants regained about two-thirds of the weight they had lost

This is a cost-containment measure that many members find frustrating, particularly when their provider believes a GLP-1 is the most appropriate treatment from the outset

Cognitive enhancement treatments for bipolar disorder: a systematic review and methodological recommendations

These classes were also associated with similar relative risk reductions in all-cause (12%-15%) and CV mortality (13%-15%)